{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:59:00Z","timestamp":1790704740713,"version":"4.1.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1097\/mpa.0b013e318279b87f","type":"journal-article","created":{"date-parts":[[2013,2,21]],"date-time":"2013-02-21T18:29:44Z","timestamp":1361471384000},"page":"813-818","source":"Crossref","is-referenced-by-count":68,"title":["Disrupting Cytokine Signaling in Pancreatic Cancer"],"prefix":"10.1097","volume":"42","author":[{"given":"Christina","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soledad A.","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Criswell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek A.","family":"Chidiac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Guttridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Villalona-Calero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanios S.","family":"Bekaii-Saab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-9-20210212","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/0960327111417271","article-title":"The relationship among acute-phase response proteins, cytokines, and hormones in various gastrointestinal cancer types patients with cachectic.","volume":"31","author":"Kemik","year":"2012","journal-title":"Hum Exp Toxicol"},{"key":"R3-9-20210212","doi-asserted-by":"crossref","first-page":"5802","DOI":"10.1158\/1078-0432.CCR-05-0185","article-title":"Role of mononuclear cells and inflammatory cytokines in pancreatic cancer-related cachexia.","volume":"11","author":"Martignoni","year":"2005","journal-title":"Clin Cancer Res"},{"key":"R4-9-20210212","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.2337\/diabetes.51.5.1319","article-title":"Tumor necrosis factor-alpha suppresses adipocyte-specific genes and activates expression of preadipocyte genes in 3T3-L1 adipocytes: nuclear factor-kappaB activation by TNF-alpha is obligatory.","volume":"51","author":"Ruan","year":"2002","journal-title":"Diabetes"},{"key":"R5-9-20210212","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1210\/jc.2007-1761","article-title":"TNF-alpha modulates human in vivo lipolysis.","volume":"96","author":"Plomgaard","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"R6-9-20210212","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.bbrc.2007.03.202","article-title":"Wnt-signaling is maintained and adipogenesis inhibited by TNF but not MCP-1 and resistin.","volume":"357","author":"Hammerstedt","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"R7-9-20210212","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1126\/science.289.5488.2363","article-title":"NF-kappaB induced loss of MyoD messenger mRNA: possible role in muscle decay and cachexia.","volume":"289","author":"Guttridge","year":"2000","journal-title":"Science"},{"key":"R8-9-20210212","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1097-2765(04)00211-4","article-title":"The IGF-1PI3KAkt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors.","volume":"14","author":"Stitt","year":"2004","journal-title":"Mol Cell"},{"key":"R9-9-20210212","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.cell.2004.09.027","article-title":"IKKNF-kappaB activation causes severe muscle wasting in mice.","volume":"119","author":"Cai","year":"2004","journal-title":"Cell"},{"key":"R10-9-20210212","doi-asserted-by":"crossref","first-page":"4258","DOI":"10.1038\/sj.onc.1204559","article-title":"CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-kappaB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin.","volume":"20","author":"Trauzold","year":"2001","journal-title":"Oncogene"},{"key":"R11-9-20210212","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1158\/0008-5472.CAN-07-5704","article-title":"Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis.","volume":"68","author":"Egberts","year":"2008","journal-title":"Cancer Res"},{"key":"R12-9-20210212","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group.","volume":"342","author":"Lovell","year":"2000","journal-title":"N Engl J Med"},{"key":"R13-9-20210212","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa030409","article-title":"Etanercept as monotherapy in patients with psoriasis.","volume":"349","author":"Leonardi","year":"2003","journal-title":"N Engl J Med"},{"key":"R14-9-20210212","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/art.11325","article-title":"Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.","volume":"48","author":"Davis","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R15-9-20210212","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"R16-9-20210212","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.","volume":"15","author":"Burris","year":"1997","journal-title":"J Clin Oncol"},{"issue":"8","key":"R17-9-20210212","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.4049\/jimmunol.160.8.3942","article-title":"Lymphocytes produce IL-1beta in response to Fcgamma receptor cross-linking: effects on parenchymal cell IL-8 release.","volume":"160","author":"Marsh","year":"1998","journal-title":"J Immunol"},{"key":"R18-9-20210212","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1182\/blood.V97.10.3146","article-title":"Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset.","volume":"97","author":"Cooper","year":"2001","journal-title":"Blood"},{"key":"R19-9-20210212","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.4049\/jimmunol.162.8.4511","article-title":"Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response.","volume":"162","author":"Fehniger","year":"1999","journal-title":"J Immunol"},{"key":"R20-9-20210212","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.","volume":"25","author":"Moore","year":"2007","journal-title":"J Clin Oncol"},{"key":"R21-9-20210212","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRNOX versus gemcitabine for metastatic pancreatic cancer.","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"R22-9-20210212","doi-asserted-by":"crossref","first-page":"478","DOI":"10.7326\/0003-4819-130-6-199903160-00004","article-title":"Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.","volume":"130","author":"Moreland","year":"1999","journal-title":"Ann Intern Med"},{"key":"R23-9-20210212","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1200\/JCO.2005.04.127","article-title":"Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer.","volume":"23","author":"Madhusudan","year":"2005","journal-title":"J Clin Oncol"},{"key":"R24-9-20210212","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1136\/gut.2004.047563","article-title":"Thalidomide in the treatment of cancer cachexia: a randomized placebo controlled trial.","volume":"54","author":"Gordon","year":"2005","journal-title":"Gut"},{"key":"R25-9-20210212","first-page":"18","article-title":"A multicenter, phase ii study of infliximab plus gemcitabine in pancreatic cancer cachexia.","volume":"6","author":"Widenmann","year":"2008","journal-title":"J Support Oncol"},{"key":"R26-9-20210212","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1074\/jbc.M207129200","article-title":"Tumor necrosis factor-regulated biphasic activation of NF-kappa B is required for cytokine-induced loss of skeletal muscle gene products.","volume":"278","author":"Ladner","year":"2003","journal-title":"J Biol Chem"},{"key":"R27-9-20210212","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/00000658-199404000-00001","article-title":"Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer.","volume":"219","author":"Falconer","year":"1994","journal-title":"Ann Surg"},{"key":"R28-9-20210212","first-page":"4311","article-title":"Tumor necrosis factor alpha (TNF-alpha) gene therapy targeted by ionizing radiation selectively damages tumor vasculature.","volume":"56","author":"Mauceri","year":"1996","journal-title":"Cancer Res"},{"key":"R29-9-20210212","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nm0895-786","article-title":"Spatial and temporal control of gene therapy using ionizing radiation.","volume":"8","author":"Hallahan","year":"1995","journal-title":"Nat Med"},{"key":"R31-9-20210212","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0002-9440(10)65149-8","article-title":"Tumor-associated transforming growth factor-b and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients.","volume":"155","author":"Bellone","year":"1999","journal-title":"Am J Pathol"},{"key":"R32-9-20210212","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/01.mpa.0000191651.32420.41","article-title":"Differences in immune cells engaged in cell-mediated immunity after chemotherapy for far advanced pancreatic cancer.","volume":"32","author":"Bang","year":"2006","journal-title":"Pancreas"},{"key":"R33-9-20210212","first-page":"925s","article-title":"Systemic and local immunosuppression in pancreatic cancer patients.","volume":"7","author":"Von Bernstroff","year":"2001","journal-title":"Clin Cancer Res"}],"container-title":["Pancreas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPA.0b013e318279b87f","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T09:50:26Z","timestamp":1714989026000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006676-201307000-00009"}},"subtitle":["A Phase I\/II Study of Etanercept in Combination With Gemcitabine in Patients With Advanced Disease"],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/mpa.0b013e318279b87f","relation":{},"ISSN":["0885-3177"],"issn-type":[{"value":"0885-3177","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}